Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
Blue curve MMWR spacer

The content on this page is being archived for historic and reference purposes only. The content, links, and pdfs are no longer maintained and might be outdated.

Notice to Readers Bacterial Sepsis Associated with Receipt of Albumin

The Food and Drug Administration (FDA) has designated as Class I (defined by FDA as a strong likelihood that a product will cause serious adverse health consequences or death) a recall of Centeon Albumin, 25% (Human), U.S.P., Albuminar{Registered}-25 (manufactured by Centeon L.L.C., King of Prussia, Pennsylvania), lot number P61205, because of Enterobacter cloacae sepsis associated with receipt of product from this lot. Contamination of the product may have been due to cracks in the vials during manufacture. Cultures of unopened product grew Stenotrophomonas multophilia and enterococci in addition to E. cloacae. Ten other lots (P18607, L8212, M60902, M54512, L58211, M61403, M63204, M54912, P61805, and P62906) of Centeon Albuminar{Registered}-25 and Albuminar{Registered}-5 (albumin, 5% {human}, U.S.P.) also have been recalled as a precaution because of the potential for contamination due to similar manufacturing problems.

Hospitals, dialysis centers, and other users should discontinue use of these lots of Centeon Albuminar{Registered} and quarantine all vials belonging to these lots. Other lots should not be used if the vials are visibly cracked or the contents are visibly turbid. Health-care professionals should report any episode of infection associated with Centeon Albuminar{Registered} to CDC's Hospital Infections Program, National Center for Infectious Diseases (telephone {404} 639-6413; fax {404} 639-6459), and to FDA's MedWatch Program (telephone {800} 332-1088; fax {800} 332-0178).

Centeon also is voluntarily recalling a single lot (P72304) of Monoclate-P{Registered} Factor VIII used to treat hemophilia; no adverse events have been reported in association with Monoclate-P {Registered}. The investigation by FDA and Centeon is ongoing, and additional information is available from FDA's Center for Biologics Evaluation and Research, telephone (301) 827-2000 or (800) 835-4709.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to

Page converted: 09/19/98


Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A


Department of Health
and Human Services

This page last reviewed 5/2/01